OptiBac Probiotics Revenue and Competitors

Claim your profile

Andover, UK

Location

N/A

Total Funding

Health

Industry

Estimated Revenue & Valuation

  • OptiBac Probiotics's estimated annual revenue is currently $15.3M per year.(i)
  • OptiBac Probiotics's estimated revenue per employee is $243,000

Employee Data

  • OptiBac Probiotics has 63 Employees.(i)
  • OptiBac Probiotics grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A0N/AN/AN/A
#2
$21.6M80-1%N/AN/A
#3
$102.3M303-2%N/AN/A
#4
$18M74-16%N/AN/A
#5
$7.6M35-39%N/AN/A
#6
$21.9M81-2%N/AN/A
#7
$908M24027%N/AN/A
#8
$121.2M359-1%N/AN/A
#9
$15.6M64-4%N/AN/A
#10
$138.7M411-3%N/AN/A

OptiBac Probiotics is the UK's best-selling probiotic range. Specialising in probiotics such as L. acidophilus, OptiBac Probiotics have a range of probiotic products, using different strains to target different health conditions, such as bloating, diarrhoea, immunity, children's health and travel health. The entire range is free from artificial sweeteners and flavourings, and also much more potent than probiotic yoghurts or yoghurt drinks.

keywords:N/A

N/A

Total Funding

63

Number of Employees

$15.3M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

OptiBac Probiotics News

04/04/2019 - The Truth About Taking Probiotics For Your Vagina

Health brands now manufacture probiotics that purport to boost our vaginal health. There's OptiBac "For women", Canesten's "Canesflor probiotics for vaginal ...

07/26/2019 - Local business scoops royal award

Wren Laboratories Ltd is the company behind OptiBac Probiotics, the UK & Ireland's most popular brand of probiotic supplements*.

01/24/2019 - Is it worth taking probiotics after antibiotics?

Probiotics have been touted as a treatment for a huge range of conditions, from obesity to mental health problems. One of their popular uses is ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A6410%N/A
#2
$17.6M70N/AN/A
#3
$15.4M709%N/A
#4
$7.8M7233%N/A
#5
$7.9M77N/AN/A